Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 128,557

Document Document Title
WO/2017/149392A1
Disclosed are stable self-emulsifying compositions comprising at least one CB2 receptor modulator, a self-emulsifying vehicle and optionally at least one antipsychotic agent for use in the treatment of mental disorders, methods of prepar...  
WO/2017/149503A1
Human mutated form of NGF comprising two mutations, a first mutation being represented by the substitution of the proline amino acid in position 61 with a serine, a second mutation being represented by the substitution of an amino acid i...  
WO/2017/148406A1
The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutic...  
WO/2017/151687A1
Compositions and methods for reducing the level of prions in a prion-infected cells or host by exposing prion infected cells, tissues and organs to AR-12 and the AR-12 analog AR-14 to reduce the prion level by at least about 90%.  
WO/2017/149469A1
Present invention relates to novel heterocyclic compounds as indoleamine 2,3- dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) modulators. Compounds of the present invention inhibit tryptophan degradation by modulating IDO and/o...  
WO/2017/150477A1
The purpose of the present invention is to provide a compound having an excellent JAK1-inhibiting activity. The compound according to the present invention has a JAK1-inhibiting activity, and therefore has an immunesuppressing effect, an...  
WO/2017/151006A1
The group of inventions relates to medicine and pharmacology, and more particularly to psychiatry, and can be used for the effective and safe treatment of psychiatric disorders associated with dysfunction in the dopamine and serotonin ne...  
WO/2017/151644A1
The present disclosure relates to oligonucleotide decoys, pharmaceutical compositions thereof, and the use of such to modulate nociceptive signaling and to prevent and/or treat pain.  
WO/2017/150228A1
The present invention addresses the problem of providing an efficacious means against muscle atrophy. Provided is a muscle atrophy inhibitor that comprises, as active ingredient(s): (1) one or more proteins selected from the group consis...  
WO/2017/151980A1
Disclosed are compositions and methods for mitigating a tolerance effect from ingestion of cannabis-based medicines in human subjects, for example, subjects having an increased risk of unresponsiveness to one or more therapeutic agents s...  
WO/2017/149333A1
The invention relates to C-3 substituted kynurenic acid derivatives with the general formula (I) wherein R1 is C1-7alkyl-, R6R7N-C1-7alkyl-, C6-10aryl-C1-7alkyl group; R2 is H or C1-7alkyl group; or R1 and R2 with the nitrogen atom to wh...  
WO/2017/149534A1
The present disclosure generally relates to nicotine formulations, nebulizer systems comprising same and uses thereof via inhalation.  
WO/2017/150704A1
An aquaporin 4 function promoter contains, as an active ingredient, a compound represented by general formula (1) or (2) or a pharmacologically acceptable salt thereof. (In the formulas, n11 is an integer of 1-10. R21 is a C1-10 alkyl gr...  
WO/2017/147654A1
The present invention relates to a method of treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject, comprising treating the subject to: (a) promote phosphorylation of one o...  
WO/2017/147719A1
A method of treating a neuropathy, such as a recessive neuronopathy or peripheral neuropathy, in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of exosomes genetically engineered...  
WO/2017/150475A1
[Problem] To develop a brain health food/brain health beverage for preventing/alleviating brain atrophy due to alcohol intake. [Solution] A brain health food or brain health beverage containing, as active ingredients, folic acid, vitamin...  
WO/2017/147720A1
A method of treating a central nervous system disorder in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of non-naturally occurring exosomes engineered to comprise nucleic acid e...  
WO/2017/149339A1
The present invention relates to compounds of formula (I), which are blocked in C3 position and cannot metabolize in vivo into pregnenolone derivatives and which do not have significant affinity for steroid hormonal receptors and for all...  
WO/2017/150686A1
The present invention provides a composition that is effective in improving the symptoms of autism spectrum disorder. The composition is characterized in containing, as an active ingredient, at least one type of pyridoxamine compound sel...  
WO/2017/150327A1
The present invention addresses the problem of providing a food material that is added to food to promote in-brain secretion of neurotrophins including BDNF, and that can endow the food with a brain function improvement function and a cr...  
WO/2017/148960A1
The present invention relates to compositions for use in the treatment of neurological disease. In one embodiment, the present invention relates to a peptide analogue of xenin or gastric inhibitory polypeptide for use in the treatment of...  
WO/2017/150566A1
The present invention provides a model animal for establishing an effective treatment for protein aggregate diseases typified by Alzheimer's disease and the like. More specifically, the present invention provides the following. (A) A non...  
WO/2017/149387A1
Disclosed are stable compositions comprising at least one CB2 receptor selective or highly selective agonist and optionally at least one antipsychotic for use in the treatment of mental disorders, methods of preparing such compositions a...  
WO/2017/147285A9
The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.  
WO/2017/147147A1
Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising a Nav1.7 selective inhibitor and a biodegradable carrier, wherein the agent is incorporated within the biodeg...  
WO/2017/147285A1
The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.  
WO/2017/147536A1
Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disea...  
WO/2017/143990A1
The present invention provides a method for preparing a pyrrolopyrimidine compound and application thereof. Specifically, the present invention provides a compound represented by formula I or pharmaceutically-acceptable salts thereof, a ...  
WO/2017/146230A1
The purpose of the present invention is to provide an extract from inflammatory tissue inoculated with vaccinia virus, a test method using a novel method of administration of a formulation containing the extract, and the like. With the p...  
WO/2017/147529A1
The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associat...  
WO/2017/143967A1
A poly(butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system with the nanoparticle, and a preparation method for the nanoparticle and the system. A surface of the nanoparticle is modified by a first modifying ...  
WO/2017/146104A1
An oral cavity patch that comprises a drug layer, said drug layer containing a drug and an infiltration promoter, and an adhesive layer, said adhesive layer containing a mucosa adhering property-imparting component and being fixed to the...  
WO/2017/144393A1
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting 2-substituted 5-(phenyl)-1,2-dihydro-3H-3-benzazepine-3-carboxamide derivatives of general formula (I), where R...  
WO/2017/144995A1
A compound compound having the structure (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A' and A" are independently O, C=O, C-R...  
WO/2017/143836A1
Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharm...  
WO/2017/145166A1
The present invention provides a composition and method for treating, delaying the onset, delaying progression of, reducing the incidence of or reducing the severity of amyotrophic lateral sclerosis, in a subject. The composition in some...  
WO/2017/147375A1
The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cup...  
WO/2017/147379A1
The present invention provides the use of compounds which selectively block the Nav1.1 subtype of voltage-gated sodium (Nav) channels, whose role in nociception and pain has been unexplored. The present invention demonstrates that Nav1.1...  
WO/2017/145013A1
The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R 3, and R 4are as defined herein. The invention is also directed to pharmaceutical c...  
WO/2017/143397A1
The present invention relates to compounds and their uses. In particular, to compounds that inhibit the interaction between β-arrestin and the intracellular C-terminus of the activated NK1R and their use in the treatment of pain.  
WO/2017/144637A1
The invention relates to acid addition salts of piperazine derivatives, as well as solid forms, such as polymorphic forms, thereof, which are useful as pharmaceutical ingredients and in particular as glycosidase inhibitors.  
WO/2017/143451A1
Antibodies to human CD11d, compositions comprising such CD11d antibodies, and methods of using such CD11d antibodies for the treatment of central nervous system trauma including spinal cord injury and traumatic brain injury, as well as s...  
WO/2017/146053A1
Provided are: pharmaceutical composition particles and an orally disintegrating tablet including the same which are capable of achieving both the masking of unpalatable taste and an improvement in elution properties; and a method for pro...  
WO/2017/147414A1
The present disclosure relates in general to therapeutic lysosomal enzyme fusion proteins useful for treating lysosomal storage diseases, liquid formulations comprising such fusion proteins and associated methods useful for treating lyso...  
WO/2017/140684A2
The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction...  
WO/2017/142424A1
Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have, or are at risk for, Alzheimer's disease comprising tetramine copper chelators in combination with an agent effective to reduce one or more...  
WO/2017/142442A1
The invention relates to the field of medicine and to the chemical-pharmaceutical industry, and pertains to agents for use in the case of sleep disorders. A pharmaceutical composition for initiating and maintaining the sleep process and ...  
WO/2017/140212A1
Provided are a use of Zn7MT3 and derivatives thereof in treating Alzheimer's disease and the use of same in preparing drugs against Alzheimer's disease and neurodegenerative diseases. Also provided is a preparation method for Zn7MT3.  
WO/2017/139971A1
The present invention relates to a crystal form N of aripiprazole, a pharmaceutical composition thereof and the use of the new crystal form in the preparation of a medicine for treating central nervous system diseases, especially schizop...  
WO/2017/139845A1
The invention relates to alpha conotoxin (α-conotoxin) peptides and methods for their preparation. Also described are pharmaceutical compositions comprising alpha conotoxin (α-conotoxin) peptides and their use in the treatment or preve...  

Matches 701 - 750 out of 128,557